Investor Relations


Zogenix, Inc. (Nasdaq: ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
NASDAQ | ZGNX (Common Stock)
$9.92 - 0.08
Stock chart for: ZGNX.O.  Currently trading at $9.92 with a 52 week high of $21.65 and a 52 week low of $7.90.
Data as of 05/27/16 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.

Latest Presentations

Zogenix April 2016 Investor Presentation
Download Documentation

Recent News More

Zogenix Provides Corporate Update and Reports First Quarter 2016 Financial Results

Read More

Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome

Read More

Investor Events More

Tuesday, May 10, 2016 4:30 p.m. ET
Q1 2016 Zogenix, Inc. Earnings Conference Call